SV

Street Verdict

Analyst Scorecard

NATCOPHARM · NSE

Natco Pharma Limited

₹814.3

-0.93% (-₹7.65)

Prev. close

₹821.95

Volume

5,59,245

Delivery %

48.3%

As of

20 Nov 2026

Price history

₹814.3-₹84.05 (-9.36%) · 3M
18 Aug 2026 → 20 Nov 2026
80082084086088018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 3 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Natco Pharma Limited

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Rajeev Nannapaneni

Headquarters

Hyderabad

Employees

4,433

Key stats

Market cap

₹15,472.75 Cr

P/E ratio (TTM)

12.4

Dividend yield

0.76%

EPS (TTM)

₹63.37

Beta (1Y · daily vs NIFTY 50)

0.86

Beta (5Y · monthly vs NIFTY 50)

0.92

Shares float

9.21 Cr

EPS · quarter ended Jun 2026

₹11.53

Financial Performance

01 · Financials

0 Cr2000 Cr4000 Cr6000 Cr₹0%20%40%60%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

050100150₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0358₹-50%0%50%100%24 Feb 2026 Jun 2021 Aug 2024 Nov 2022 Feb 2124 Aug 2123 Nov 2124 Feb 2219 Aug 2221 Nov 2221 Feb 2322 Aug 2324 Nov 2326 Feb 2423 Aug 2427 Nov 2418 Feb 2519 Aug 2520 Nov 2518 Feb 2620 Aug 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr5000 Cr10000 Cr15000 Cr₹0×0.25×0.5×0.75×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr5000 Cr10000 Cr15000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-1000 Cr0 Cr1000 Cr2000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2,052.10 Cr₹1,944.80 Cr₹2,707.10 Cr₹3,998.80 Cr₹4,429.50 Cr₹4,078.30 Cr
EBITDA
₹709.80 Cr₹362.50 Cr₹1,040.20 Cr₹1,879.50 Cr₹2,550.50 Cr₹1,734.10 Cr
₹440.90 Cr₹170.00 Cr₹715.30 Cr₹1,388.30 Cr₹1,885.40 Cr₹1,418.50 Cr
Diluted EPS
₹24.16₹9.32₹39.18₹77.34₹105.26₹79.2

Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Pretax income, Tax provision, Interest expense, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹4,791.90 Cr₹5,109.10 Cr₹5,657.40 Cr₹6,906.30 Cr₹8,630.80 Cr₹11,073.70 Cr
——₹176.10 Cr₹371.20 Cr₹279.40 Cr₹713.90 Cr
Stockholders' equity
₹4,121.60 Cr₹4,263.60 Cr₹4,873.80 Cr₹5,853.10 Cr₹7,607.00 Cr₹9,221.10 Cr

Fixed assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹298.80 Cr₹46.50 Cr₹849.10 Cr₹1,211.60 Cr₹1,696.80 Cr₹1,768.30 Cr
Investing cash flow
₹-103.30 Cr₹-5.30 Cr₹-477.10 Cr₹-1,032.70 Cr₹-1,414.50 Cr₹-2,081.70 Cr
₹-185.70 Cr₹34.80 Cr₹-363.00 Cr₹-246.90 Cr₹-210.70 Cr₹297.50 Cr
Capital expenditure
₹-441.50 Cr₹-272.00 Cr₹-205.60 Cr₹-358.70 Cr₹-511.60 Cr₹-391.10 Cr
End cash position
₹25.80 Cr₹111.10 Cr₹131.90 Cr₹70.40 Cr₹120.00 Cr₹198.90 Cr

Depreciation & amortization, Change in working capital, Debt issued, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22Jun 22–Sep 22(2Q)Dec 22Mar 23Jun 23Sep 23–Jun 24(4Q)Sep 24–Dec 24(2Q)Mar 25–Jun 25(2Q)Sep 25–Dec 25(2Q)Mar 26–Jun 26(2Q)
Promoter48.87%48.86%48.81%48.80%48.82%48.84%49.76%49.71%49.62%49.56%49.48%49.42%
Public51.13%51.14%51.19%51.20%51.18%51.16%50.24%50.29%50.38%50.44%50.52%50.58%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Natco Pharma Limited₹15,332.49 Cr₹788.7512.31.6615.4%0.08-8.3%-3.8%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

NATCOPHARM

NATCO Pharma's (NSE:NATCOPHARM) Problems Go Beyond Weak Profit

Simply Wall St · 2 days ago

NATCOPHARM

Natco Pharma Q2 FY27 revenue falls 30% as profit drops 61%

Multibagg AI · 4 days ago